CVS Health (CVS) option implied volatility elevated into EPS and outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Mizuho Securities Reiterates Buy Rating on CVS Health (CVS) Following 3Q EPS Beat
November 7, 2019 6:55 AM ESTMizuho Securities analyst Ann Hynes reiterated a Buy rating and $71.00 price target on CVS Health (NYSE: CVS) following the company's 3Q earnings report. CVS reported 3Q:19 EPS of $1.84, above consensus of $1.76. Adjusted operating profit was $3.947bn versus consensus at $3.89bn.
The tone of... More
